Abstract:Background: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. Methods: In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0·97, 95% CI 0·87-1·07; p=0·50). No significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1·04, 95% CI 0·98-1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0·95, 95% CI 0·87-1·03; p=0·24). Interpretation: In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research.

The Efficacy and Safety of Azithromycin in Acute Community-Acquired Low Respiratory Infection

Multicenter Clinical Evaluation of Domestic Azithromycin Injection in the Treatment of Bacterial Infections

Clinical evaluation of azithromycin sequential therapy in the treatment of 138 patients with community-acquired pneumonia

Clinical Comparative Study of Injectable Azithromycin and Cefuroxime in the Treatment of Lower Respiratory Tract Infection

Clinical evaluation of azithromycin

A Randomized Controlled Clinical Trial on Injective Azithromycin Versus Erythromycin in the Treatment of Respiratory Tract Bacterial Infections.

The Efficacy and Safety of Azithromycin in Asthma: A Systematic Review

Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection

Efficacy and Safety of Roxithromycin/ambroxol Dispersible Tablets in Patients with Acute Bacterial Lower Respiratory Tract Infection

A randomized controlled clinical study of aztraonam in treatment of 60 elderly patients with low respiratory tract bacterial infections

Efficacy and safety of Azithromycin and Erythromycin for respiratory mycoplasma infection in children: a meta-analysis

Efficacy and safety of roxithromycin/ambroxol in patients with lower respiratory tract infection

Comparison of omadacycline and meropenem plus linezolid in treatment of pulmonary infection: A real-world cohort study

Efficacy and safety of azithromycin eye drops in treatment of bacterial conjunctivitis: a Meta-analysis

Clinical Efficacy of Azithromycin in Treatment of Children’s Mycoplasma Pneumonia

Early target attainment of azithromycin therapy in children with lower respiratory tract infections

Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia

Clinical Efficacy of Azithromycin in the Treatment of Pediatric Mycoplasma pneumoniae Pneumonia and Its Impact on Platelet Count and D-Dimer Levels

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Cefaclor in treatment of secondary lower respiratory tract infections in chronic obstructive pulmonary diseases

Multi-center, randomized, blinded, parallel control clinical study of cefazedone injection and cefazolin injection in the treatment of acute bacterial respiratory infections